Recent Updates
Recently added Catalysts

Paxil manufactured by SmithKline Beecham Limited- Cidra- Puerto Rico

Phase 1

Depressive Disorder | Small molecule | Psychiatry |GSK plc|Last Updated: Jun 20, 2018

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment60

FDA Designations

No designations recorded

Clinical trial landscape

Paxil manufactured by SmithKline Beecham Limited- Cidra- Puerto Rico · 1 trial · 1 indication

Phase 1 1
NCT01339247Paxil CR Bioequivalence Study Brazil - Fed AdministrationDepressive Disorder
COMPLETED60 Analytics
PHASE1COMPLETED
Paxil CR Bioequivalence Study Brazil - Fed Administration
Depressive DisorderUnlock trial analytics

Study Endpoints

Primary Endpoints

AUC_ss
Days 14 to 17 (period 1) and Days 23 to 24 (Period 2)

The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC\_ss is the area under the curve during the steady-state period. The AUC\_ss is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. ng, nanograms; h, hour; ml, milliliter; ng.h/ml, nanograms per hour per milliliter.

Cmin_ss
Days 14 to 17 (period 1) and Days 23 to 24 (Period 2)

Cmin\_ss is defined as the minimum concentration of a drug observed after its administration, in steady-state. Cmin\_ss is one of the parameters of particular use in estimating the bioavailability of drugs, for studies employing multiple doses.

Cmax_ss
Days 14 to 17 (period 1) and Days 23 to 24 (Period 2)

Cmax\_ss is defined as the maximum or "peak" concentration of a drug observed after its administration, in steady-state. Cmax\_ss is one of the parameters of particular use in estimating the bioavailability of drugs, by measuring the total amount of drug absorbed.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
Paxil CR ReferenceACTIVE_COMPARATORParoxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico, in Period 1, followed by Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada, in Period 2
Paxil CR TestACTIVE_COMPARATORParoxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada, in Period 1, followed by Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico, in Period 2

Interventions

NameTypeDescription
Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto RicoDRUGParoxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - CanadaDRUGParoxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 40 Years
SexALL
Healthy VolunteersYes
Study Sites1

EXCLUSION CRITERIA: * hypersensitivity to the study drug or to compounds chemically related; * history of serious adverse events; * concurrent or recent use of other antidepressives, schizophrenia, anticonvulsant; * History of liver, heart, gastrointestinal or renal illness; * ECG findings not reco...

Countries:Brazil
Unlock Eligibility Criteria